Hormonal
Obesity, insulin resistance, and type 2 diabetes are pathological conditions associated with exaggerated and prolonged postprandial lipemia, characterized by delayed clearance of triacylglycerol-rich lipoproteins (TRL).
If you have obesity, insulin resistance, or type 2 diabetes, your body may struggle to clear fat from your blood after meals, leading to higher and longer-lasting triglyceride levels. This delayed clearance is a significant risk factor for heart disease, even if your fasting cholesterol looks okay. Managing these conditions through lifestyle and medication can help improve postprandial lipid clearance.
Obesity is associated with an exaggerated postprandial lipaemia... Subjects with fasting hypertriacylglycerolaemia are known to display exaggerated and prolonged postprandial lipid responses... Type 2 diabetes mellitus is associated with a marked increase in risk of CVD... Both fasting and postprandial plasma remnant lipoprotein-cholesterol were elevated
Why this rating
Multiple studies support the association.
Source
Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism
José López‐Miranda et al. · British Journal Of Nutrition · 2007
DOI 10.1017/s000711450774268x
More from this paper
- Postprandial lipemia, specifically the delayed clearance of triacylglycerol-rich lipoproteins (TRL) and their remnants, is a significant independent risk factor for the development and progression of atherosclerosis and coronary heart disease (CHD).Good
- Dietary fat type influences postprandial lipemia, with long-chain n-3 polyunsaturated fatty acids (PUFA) from fish oil significantly reducing postprandial triacylglycerol levels compared to saturated (SFA) or monounsaturated (MUFA) fats, provided sufficient doses (2.7-4 g/d) are consumed.Good
- Physical activity, particularly aerobic exercise performed before a meal, significantly reduces postprandial lipemia and increases lipoprotein lipase (LPL) activity, improving lipid clearance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →